The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMinerva Neurosciences (Nasdaq: NERV) has officially commenced the screening of the first patient in its global Phase 3 clinical trial for roluperidone. This confirmatory study is designed to evaluate the drug's efficacy as a monotherapy for treating the negative symptoms of schizophrenia. The trial represents a critical milestone for the clinical-stage biotech company as it seeks to secure regulatory approval from the FDA. According to the company's timeline, topline efficacy data from this pivotal study is expected to be released in the second half of 2027. Addressing negative symptoms remains a high unmet need in the schizophrenia treatment landscape, positioning roluperidone as a potential breakthrough. While the data readout is several years away, the progression into Phase 3 de-risks the company's pipeline and maintains its growth trajectory.